US12629400B2 - Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals - Google Patents

Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals

Info

Publication number
US12629400B2
US12629400B2 US18/754,975 US202418754975A US12629400B2 US 12629400 B2 US12629400 B2 US 12629400B2 US 202418754975 A US202418754975 A US 202418754975A US 12629400 B2 US12629400 B2 US 12629400B2
Authority
US
United States
Prior art keywords
organic solvent
leaves
stems
pharmaceutical composition
coarse powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US18/754,975
Other versions
US20250000925A1 (en
Inventor
Kwasi Adomako Ohemeng
Peace Mawunyo Doe
Samuel Nda Blay Armah
Kwabena Oteng-Boahen
Vanessa Naomi Opare
Paul Asong Lartey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lagray Inc
Equatorial Healthcare Services
Original Assignee
Lagray Inc
Equatorial Healthcare Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lagray Inc, Equatorial Healthcare Services filed Critical Lagray Inc
Priority to US18/754,975 priority Critical patent/US12629400B2/en
Assigned to EQUATORIAL HEALTHCARE SERVICES, LaGray, Inc. reassignment EQUATORIAL HEALTHCARE SERVICES ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: LARTEY, PAUL A., DR., ARMAH, SAMUEL BLAY, MR., DOE, PEACE MAWUNYO, MS., OHEMENG, KWASI ADOMAKO, DR., OPARE, VANESA NAOMI, MS., OTENG-BOAHEN, KWABENA, MR.
Publication of US20250000925A1 publication Critical patent/US20250000925A1/en
Priority to PCT/US2025/032869 priority patent/WO2026005977A1/en
Application granted granted Critical
Publication of US12629400B2 publication Critical patent/US12629400B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition having antibiotic qualities is disclosed. The pharmaceutical composition includes a plurality of leaves and stems of the plant Justicia secunda, wherein the plurality of leaves and stems dried and pulverized to form a coarse powder; and an organic solvent, the coarse powder combined with the organic solvent for one to ten days, but preferably seven days, to form an organic solvent extract that yields a powder composition under column chromatography.

Description

CROSS-REFERENCE TO RELATED APPLICATION
This claims the benefit of priority to U.S. Provisional Patent Application No. 63/523,811 filed Jun. 28, 2023, which is incorporated by reference herein in its entirety.
TECHNICAL FIELD
The present invention relates to pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals. More specifically, the present invention relates to preparation and uses of extracts and compositions of the plant Justicia secunda.
BACKGROUND
Antimicrobial resistance is currently a major problem in the treatment of infectious diseases, as bacterial species are becoming increasingly resistant to existing antibacterial drugs. Bacterial species such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci (VRE) and drug resistant Streptococcus pneumoniae (DRSP) are resistant to several major classes of antibacterial drugs. Examples of such antibacterial drugs are the quinolone ciprofloxacin, the tetracycline minocycline and the glycopeptide vancomycin. There is therefore an urgent need for novel antibacterial drugs, especially pharmaceutical compositions that are effective in treating infections by resistant strains of bacteria including MRSA, VRE and DRSP.
As recognized by those skilled in the art, most antibacterial drugs in current use are compositions of microbial fermentation extracts, semi-synthetic derivatives of such compositions or compounds obtained through organic synthesis. For example, ciprofloxacin is a purely synthetic compound, minocycline is a semi-synthetic derivative of a composition from the fermentation of a strain of Streptomyces aurofaciens, and vancomycin is a composition from the fermentation of a strain of Amycolatopsis orientalis.
This invention relates to the use of extracts, fractions, or compositions of a plant which to our surprise, have potent activity against bacteria. More particularly, the invention relates to pharmaceutical compositions derived from an organic solvent extract of the plant Justicia secunda and their use in the treatment or prevention of bacterial infections. These compositions are potent against bacterial strains that are either susceptible or resistant to the antibacterial drugs ciprofloxacin, minocycline and vancomycin.
SUMMARY OF THE INVENTION
According to one non-limiting aspect of the present disclosure, an example embodiment of a pharmaceutical composition having antibiotic qualities is disclosed. The pharmaceutical composition includes a plurality of leaves and stems of the plant Justicia secunda, wherein the plurality of leaves and stems dried and pulverized to form a coarse powder; and an organic solvent, the coarse powder combined with the organic solvent for one to ten days, but preferably seven days, to form an organic solvent extract that yields a powder composition under column chromatography.
According to another non-limiting aspect of the present disclosure, an example embodiment of method of preparing a pharmaceutical composition is disclosed. The method includes: providing a plurality of leaves and stems of the plant Justicia secunda; drying the plurality of leaves and stems; pulverizing the plurality of leaves and stems to form a coarse powder; providing an organic solvent; combining the coarse powder with the organic solvent for one to ten days, but preferably seven days; filtering the organic solvent to provide an organic solvent extract; and separating the organic solvent extract using column chromatography to yield a powder composition.
Additional features and advantages are described herein, and will be apparent from the following Detailed Description and the figures.
BRIEF DESCRIPTION OF THE DRAWINGS
Features and advantages of the system and method described herein may be better understood by reference to the accompanying drawings in which:
FIG. 1 is a schematic diagram of the preferred method of preparation of a pharmaceutical composition from the plant Justicia secunda, involving the preparation of an organic solvent extract of the plant and preparation of compositions of the plant from the organic solvent extract;
FIG. 2 is an illustrative representation of a thin layer chromatogram showing compositions in an organic solvent extract of the plant Justicia secunda and a discrete composition described herein and hereafter referred to as “Example 1”;
FIG. 3 shows the position in a tracing from a High-Performance Liquid Chromatography (“HPLC”) analysis of a pharmaceutical composition prepared from the organic solvent extract of Justicia secunda relating to Example 1; and
FIG. 4 shows the 13C nuclear magnetic resonance spectrum of Example 1.
A skilled artisan will appreciate the foregoing details, as well as others, upon considering the following Detailed Description of certain non-limiting embodiments of the pharmaceutical composition according to the present disclosure. One of ordinary skill also may comprehend certain of such additional details upon using system and method described herein.
DETAILED DESCRIPTION
The present invention comprises preparation and use of novel antibacterial compositions from the plant Justicia secunda. These novel compositions exert a broad spectrum of antibacterial activity towards several bacterial species and strains. In particular, the pharmaceutical compositions of this invention exert potent antibacterial activity against pathogenic bacterial strains that are resistant to conventional antibacterial drugs, including ciprofloxacin, minocycline, and vancomycin. Specifically, compositions from this invention are effective against MRSA, VRE and DRSP. A method of preparation of the pharmaceutical compositions and methods of treating bacterial infections are described.
As shown in FIG. 1 , a schematic diagram of the preferred method of preparation of a pharmaceutical composition from the plant Justicia secunda is disclosed. The preferred method relates to the preparation of an organic solvent extract of the plant and preparation of compositions of the plant from the organic solvent extract.
In a preferred embodiment and referring to FIG. 1 , parts of the plant Justicia secunda that include leaves, stems, branches, and roots, but more preferably leaves and stems, referred to as plant material are selected for use, as shown at reference numeral 12.
The plant material is dried in the sun or in an oven to a suitable dryness or moisture content, as shown at reference numeral 14.
The plant material is pulverized to provide a fine to a coarse powder, but more preferably a coarse powder, as shown at reference numeral 16.
The powder is soaked for one to ten days, but more preferably 7 days in an organic solvent such as methyl alcohol, ethyl alcohol, propyl alcohol, butyl alcohol or isopropyl alcohol, but more preferably methyl alcohol, as shown at reference numeral 18. The mixture is filtered and subjected to vacuum evaporation to provide the organic solvent extract.
The organic solvent extract is subjected to column chromatography using silica gel as the stationary phase and 10 to 30% ethyl acetate in hexane as the mobile phase, but more preferably 20% ethyl acetate in hexane, as shown at reference numeral 20.
Fractions containing compositions in the organic solvent extract are collected and analyzed by thin layer chromatography, in this particular case, using silica gel as the stationary phase and 20% ethyl acetate in hexane as the mobile phase, as shown at reference numeral 20 in FIG. 1 . Fractions containing identical compositions are pooled together. The pooled fractions are evaporated to yield the compositions as powders.
FIG. 2 is an illustrative representation of a thin layer chromatogram showing compositions in an organic solvent extract of the plant Justicia secunda. FIG. 2 also illustrates that there are at a minimum four (4) compositions of the plant in the organic solvent extract, and further shows a discrete composition dubbed Example 1, as shown at reference numeral 22 in FIG. 2 . Example 1 is prepared by the method shown in FIG. 1 .
The compositions are analyzed for purity, in accordance with the steps shown in FIG. 2 , for the TLC analysis of Example 1 and in FIG. 3 for the HPLC analysis of Example 1. The illustration of FIG. 2 shows Example 1 to be a pure chemical entity with a TLC retardation factor of approximately 0.49. The illustration of FIG. 3 likewise shows Example 1 to be a pure chemical entity with an HPLC retention time of about 26.6 minutes on a C18 column.
FIG. 3 shows the position in a tracing from a High-Performance Liquid Chromatography (“HPLC”) analysis of a pharmaceutical composition prepared from the organic solvent extract of Justicia secunda. In this particular case, the HPLC results are for Example 1, as shown at reference numeral 24. This figure is presented as an illustration only, as the antibacterial properties of a second composition Example 2, derived likewise from the organic extract of Justicia secunda shall be described together with the antibacterial properties of Example 1.
FIG. 4 shows the 13C nuclear magnetic resonance spectrum of Example 1. As shown at reference numeral 26, FIG. 4 shows certain details of the 13C nuclear magnetic resonances that are characteristic of Example 1, and together with other structural data depict the molecular structure of Example 1.
Antibacterial Activity
Example 1 and Example 2 were evaluated for antibacterial activity using the agar dilution method to determine the degree of in vitro susceptibility of aerobic bacteria to the compositions from Justicia secunda. The results for the compositions are shown in TABLE I together with the results obtained for ciprofloxacin, minocycline and vancomycin, which are antibacterial drugs in current clinical use, and used herein as positive controls.
TABLE 1
MIC (μg/mL)
Positive Positive Positive
Bacterial Species Example Example Control Control Control
(Strain) 1 2 Ciprofloxacin Minocycline Vancomycin
Staphylococcus aureus 0.12 0.5 0.06 0.25 0.13
S. aureus (MRSA) 0.25 1.00 32.0 8.00 2.00
Enterococcus faecium 0.12 0.12 0.50 0.50 1.00
E. faecium (VRE) 1.00 0.5 2.00 16.0 125
Streptococcus pneumoniae 0.25 0.5 0.13 0.50 0.25
S. pneumoniae (DRSP) 0.12 1.00 2.00 16.0 0.50
Streptococcus pyogenes 1.00 0.30 0.50 0.12 0.06
Clostridium difficile 0.50 1.0 0.13 0.50 0.50
Hemophilus influenzae 0.06 0.25 0.15 0.25 0.06
Moraxella catarrhalis 0.25 0.12 0.25 0.03 0.01
Klebsiella pneumoniae 0.13 0.50 0.06 0.13 0.50
Chlamydia pneumoniae 0.25 0.25 0.12 0.50 0.50
Legionella pneumophila 0.06 0.12 0.06 0.12 0.06
As illustrated by TABLE 1, Example 1 and Example 2 are either equivalent or superior in activity to the positive controls against susceptible bacteria. Additionally, Example 1 and Example 2 are active against resistant strains such as MRSA, VRE and DRSP against which in several instances, the positive controls were ineffective.
Pharmaceutical Composition
The present invention includes one or more of the compositions of Justicia secunda, including Example 1, and pharmaceutically acceptable salts thereof, formulated together with one or more non-toxic pharmaceutically acceptable compositions such as carriers, diluents, adjuvants, binders, vehicles and the like, collectively referred to as excipients, into pharmaceutical dosage forms. In these forms, the compositions can be administered to humans and animals either orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, intraurethrally or locally.
While the present invention has been described in terms of particular embodiments and applications, in both summarized and detailed forms, it is not intended that these descriptions in any way limit its scope to any such embodiments and applications, and it will be understood that many substitutions, changes and variations in the described embodiments, applications and details of the method illustrated herein can be made by those skilled in the art without departing from the spirit and scope of this invention.
It is therefore intended that such changes and modifications be covered by the appended set of claims.

Claims (15)

What is claimed is:
1. A pharmaceutical composition comprising:
a plurality of leaves and stems of the plant Justicia secunda, the plurality of leaves and stems dried and pulverized to form a coarse powder; and
an organic solvent, the coarse powder combined with the organic solvent for at least one day to form an organic solvent extract that yields a powder composition under column chromatography.
2. The pharmaceutical composition of claim 1 wherein the organic solvent is selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, butyl alcohol, and isopropyl alcohol.
3. The pharmaceutical composition of claim 1 wherein the organic solvent is methyl alcohol.
4. The pharmaceutical composition of claim 1 wherein the coarse powder is combined with the organic solvent for more than one day but less than ten days.
5. The pharmaceutical composition of claim 1 wherein the coarse powder is combined with the organic solvent for seven days.
6. The pharmaceutical composition of claim 1 wherein the powder composition has antibacterial qualities.
7. The pharmaceutical composition of claim 1 wherein the powder composition has antibiotic qualities.
8. A method of preparing a pharmaceutical composition, the method comprising the steps of:
providing a plurality of leaves and stems of the plant Justicia secunda;
drying the plurality of leaves and stems;
pulverizing the plurality of leaves and stems to form a coarse powder;
providing an organic solvent;
combining the coarse powder with the organic solvent for at least one day;
filtering the organic solvent to provide an organic solvent extract; and
separating the organic solvent extract using column chromatography to yield a powder composition.
9. The method of claim 8 wherein the organic solvent is selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, butyl alcohol, and isopropyl alcohol.
10. The method of claim 8 wherein the organic solvent is methyl alcohol.
11. The method of claim 8 wherein the coarse powder is combined with the organic solvent for more than one day but less than ten days.
12. The method of claim 8 wherein the coarse powder is combined with the organic solvent for seven days.
13. The method of claim 8 wherein silica gel is used as the stationary phase and between 10% and 30% ethyl acetate in hexane as the mobile phase in the column chromatography.
14. The method of claim 8 wherein silica gel is used as the stationary phase and 20% ethyl acetate in hexane as the mobile phase in the column chromatography.
15. A method of preparing an antibiotic powder, the method comprising the steps of:
providing a plurality of leaves and stems of the plant Justicia secunda;
drying the plurality of leaves and stems;
pulverizing the plurality of leaves and stems to form a coarse powder;
providing a methyl alcohol solution;
combining the coarse powder with the methyl alcohol solution for at least one day;
filtering the methyl alcohol solution to provide an organic solvent extract; and
separating the organic solvent extract using column chromatography to yield an antibiotic powder composition, the column chromatography using silica gel as the stationary phase and 20% ethyl acetate in hexane as the mobile phase.
US18/754,975 2023-06-28 2024-06-26 Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals Active 2045-02-14 US12629400B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US18/754,975 US12629400B2 (en) 2023-06-28 2024-06-26 Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals
PCT/US2025/032869 WO2026005977A1 (en) 2023-06-28 2025-06-09 Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363523811P 2023-06-28 2023-06-28
US18/754,975 US12629400B2 (en) 2023-06-28 2024-06-26 Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals

Publications (2)

Publication Number Publication Date
US20250000925A1 US20250000925A1 (en) 2025-01-02
US12629400B2 true US12629400B2 (en) 2026-05-19

Family

ID=94127364

Family Applications (1)

Application Number Title Priority Date Filing Date
US18/754,975 Active 2045-02-14 US12629400B2 (en) 2023-06-28 2024-06-26 Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals

Country Status (2)

Country Link
US (1) US12629400B2 (en)
WO (1) WO2026005977A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040062823A1 (en) 2001-12-13 2004-04-01 Obukowicz Mark G. Selective cox-2 inhibition from non-edible plant extracts
US20170360862A1 (en) 2014-10-16 2017-12-21 Dong Wha Pharm. Co., Ltd. Composition containing extract or fraction of genus justicia plant
US10869904B2 (en) 2016-04-15 2020-12-22 Dong Wha Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating respiratory disease comprising extract of Justicia procumbens L
US11534471B2 (en) 2017-09-21 2022-12-27 Dana-Farber Cancer Institute, Inc. Isolation, preservation, compositions and uses of extracts from justicia plants
US20230143345A1 (en) 2020-04-09 2023-05-11 Dong Wha Pharm. Co., Ltd. Pharmaceutical composition for prevention or treatment of diseases caused by sars-cov-2
US11712056B2 (en) 2018-01-19 2023-08-01 Valbiotis Extract obtained from several plants for use in the prevention and/or treatment of chronic inflammatory bowel diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040062823A1 (en) 2001-12-13 2004-04-01 Obukowicz Mark G. Selective cox-2 inhibition from non-edible plant extracts
US20170360862A1 (en) 2014-10-16 2017-12-21 Dong Wha Pharm. Co., Ltd. Composition containing extract or fraction of genus justicia plant
US10688143B2 (en) 2014-10-16 2020-06-23 Dong Wha Pharm. Co., Ltd. Composition containing extract or fraction of genus Justicia plant
US10869904B2 (en) 2016-04-15 2020-12-22 Dong Wha Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating respiratory disease comprising extract of Justicia procumbens L
US11534471B2 (en) 2017-09-21 2022-12-27 Dana-Farber Cancer Institute, Inc. Isolation, preservation, compositions and uses of extracts from justicia plants
US11712056B2 (en) 2018-01-19 2023-08-01 Valbiotis Extract obtained from several plants for use in the prevention and/or treatment of chronic inflammatory bowel diseases
US20230143345A1 (en) 2020-04-09 2023-05-11 Dong Wha Pharm. Co., Ltd. Pharmaceutical composition for prevention or treatment of diseases caused by sars-cov-2

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Bako, "Lupeol and lauric acid isolated from ethyl acetate stem extract of Justicia secunda and their antimicrobial activity" 081-094, J. Chem. Soc. Nigeria. Online, 2023, abstract; p. 82, col. 1, para 1 and col. 2, para l; p. 83, col. 1, para 2 and col. 2, para 1; p. 92, col. 2, para 2.
Łukasz Świątek, "Chemical Characterization of Different Extracts of Justicia secunda Vahl and Determination of Their Anti-Oxidant, Anti-Enzymatic, Anti-Viral, and Cytotoxic Properties", DOI Foundation, Feb. 17, 2023, available at: https://www.mdpi.com/2076-3921/12/2/509 (last accessed Jun. 26, 2024).
Soos, "Mineral content of propolis tinctures in relation to the extraction time and the ethanol content of the extraction solvent" 719-726, LWT—Food Science and Technology. Online, May 21, 2019; <DOI: https://doi.org/10.1016/j.lwt.2019.05.090>, p. 725, col. 1, paragraph 2, and col. 2, paragraph I.
Umoh et al., Pharmacognostic evaluation of the leaves and stems of Justicia secunda Vahl. (acanthaceae). World Journal of Pharmaceutical Research (2020), 9(11Spec.Iss.), 5-18 (Year: 2020). *
Written Opinion of the International Searching Authority, dated Aug. 22, 2025, corresponding to related International Application No. PCT/US2025/032869.
Bako, "Lupeol and lauric acid isolated from ethyl acetate stem extract of Justicia secunda and their antimicrobial activity" 081-094, J. Chem. Soc. Nigeria. Online, 2023, abstract; p. 82, col. 1, para 1 and col. 2, para l; p. 83, col. 1, para 2 and col. 2, para 1; p. 92, col. 2, para 2.
Łukasz Świątek, "Chemical Characterization of Different Extracts of Justicia secunda Vahl and Determination of Their Anti-Oxidant, Anti-Enzymatic, Anti-Viral, and Cytotoxic Properties", DOI Foundation, Feb. 17, 2023, available at: https://www.mdpi.com/2076-3921/12/2/509 (last accessed Jun. 26, 2024).
Soos, "Mineral content of propolis tinctures in relation to the extraction time and the ethanol content of the extraction solvent" 719-726, LWT—Food Science and Technology. Online, May 21, 2019; <DOI: https://doi.org/10.1016/j.lwt.2019.05.090>, p. 725, col. 1, paragraph 2, and col. 2, paragraph I.
Umoh et al., Pharmacognostic evaluation of the leaves and stems of Justicia secunda Vahl. (acanthaceae). World Journal of Pharmaceutical Research (2020), 9(11Spec.Iss.), 5-18 (Year: 2020). *
Written Opinion of the International Searching Authority, dated Aug. 22, 2025, corresponding to related International Application No. PCT/US2025/032869.

Also Published As

Publication number Publication date
WO2026005977A1 (en) 2026-01-02
US20250000925A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
GB2206119A (en) A new cyclosporin derivative with modified &#34;8-amino acid&#34;
CH657139A5 (en) FACTORS 1, 2, 3, 4 AND 5 PURE ISOLATES OF TEICHOMYCIN A (2) USEFUL IN PARTICULAR AS ANTIBIOTIC DRUGS AND PROCESS FOR THEIR PREPARATION.
US5049546A (en) Antibiotic agents
Meca et al. Antibacterial effect of the bioactive compound beauvericin produced by Fusarium proliferatum on solid medium of wheat
HUP0102903A2 (en) Nocathiacin antibiotics, process for their preparation and pharmacautical compositions containing the compounds
IE57697B1 (en) Chemical process for preparing antibiotic l 17392(deglucoteicoplanin)and its salts
US20250000925A1 (en) Pharmaceutical compositions and methods for treating or preventing bacterial infections in humans and in animals
HU203906B (en) Process for producing new antibioticum named mersacidin and salts and pharmaceutical composition containing them as active components
CN102574892B (en) Antibiotic compounds
Si et al. New acylated flavonol glycosides with antibacterial activity from root barks of Sophora japonica
JPH04217988A (en) Antibiotic ge2270 factor b1, b2, c1, c2, d1, d2, e and t
KR20200067368A (en) Novel cyclic lipo-peptide-based compound having anitmicrobial activity and uses thereof
EP1805212B1 (en) Desoxo-nonadepsipeptides
EP2010202B1 (en) Antibacterial compounds
US6713448B2 (en) Substantially pure glycopeptide antibiotics AC-98-1; AC-98-2; AC-98-3; AC-98-4 and AC-98-5
KR101911892B1 (en) Macrocyclic lactam-based derivative compound, preparing method and use thereof
CN109320527B (en) Cervinomycin B1, B2, B3, B4 and its production method and application
WO2012093859A2 (en) Antifungal composition including polycyclic peptide compound and method for producing same
CN116332742B (en) Acylphloroglucinol heteroterpenoid compounds and their applications
US20050080004A1 (en) Glycopeptide composition with improved antibiotic activity
CN114014832B (en) Disc Mao Baojun ketone compound, preparation method thereof and application thereof in preparation of antibacterial drugs
CN115650946B (en) Bibenzyl derivative and preparation method and application thereof
CN121102205B (en) Application of indole-3-aryl ketone derivative in preparation of medicine for treating or preventing infectious diseases caused by staphylococcus aureus
CN120424170A (en) A cyclic lipopeptide compound, its producing bacteria, preparation method and use in preparing antibacterial drugs
EP1399176B1 (en) Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: EQUATORIAL HEALTHCARE SERVICES, GHANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LARTEY, PAUL A., DR.;OHEMENG, KWASI ADOMAKO, DR.;DOE, PEACE MAWUNYO, MS.;AND OTHERS;SIGNING DATES FROM 20240704 TO 20240705;REEL/FRAME:067920/0373

Owner name: LAGRAY, INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LARTEY, PAUL A., DR.;OHEMENG, KWASI ADOMAKO, DR.;DOE, PEACE MAWUNYO, MS.;AND OTHERS;SIGNING DATES FROM 20240704 TO 20240705;REEL/FRAME:067920/0373

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE